Induction of B7-H6, a ligand for the natural killer cell-activating receptor NKp30, in inflammatory conditions
Jessica Matta, Myriam Baratin, Laurent Chiche, Jean-Marie Forel, Céline Cognet, Guillemette Thomas, Catherine Farnarier, Christelle Piperoglou, Laurent Papazian, Damien Chaussabel, Sophie Ugolini, Frédéric Vély, Eric Vivier, Jessica Matta, Myriam Baratin, Laurent Chiche, Jean-Marie Forel, Céline Cognet, Guillemette Thomas, Catherine Farnarier, Christelle Piperoglou, Laurent Papazian, Damien Chaussabel, Sophie Ugolini, Frédéric Vély, Eric Vivier
Abstract
B7-H6, a member of the B7 family of immunoreceptors, is as a cell-surface ligand for the NKp30-activating receptor expressed on natural killer cells. B7-H6 is not detected in normal human tissues at steady state but is expressed on tumor cells. However, whether B7-H6 can be expressed in other conditions remains unknown. We analyzed here the pathways that lead to the expression of B7-H6 in nontransformed cells. In vitro, B7-H6 was induced at the surface of CD14(+)CD16(+) proinflammatory monocytes and neutrophils upon stimulation by ligands of Toll-like receptors or proinflammatory cytokines such as interleukin-1β and tumor necrosis factor α. In these conditions, a soluble form of B7-H6 (sB7-H6) was also produced by activated monocytes and neutrophils. In vivo, B7-H6 was expressed on circulating proinflammatory CD14(+)CD16(+) monocytes in a group of patients in sepsis conditions, and was linked to an increased mortality. sB7-H6 was selectively detected in the sera of patients with gram-negative sepsis and was associated with membrane vesicles that co-sedimented with the exosomal fraction. These findings reveal that B7-H6 is not only implicated in tumor immunosurveillance but also participates in the inflammatory response in infectious conditions.
Trial registration: ClinicalTrials.gov NCT00699868.
Source: PubMed